John A McCulloch
Overview
Explore the profile of John A McCulloch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
2930
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar D, Morrison R, Dzutsev A, Karunamurthy A, Chauvin J, Amatore F, et al.
Cancer Cell
. 2024 Nov;
42(11):1898-1918.e12.
PMID: 39486411
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma....
2.
Walitt B, Singh K, LaMunion S, Hallett M, Jacobson S, Chen K, et al.
Nat Commun
. 2024 Feb;
15(1):907.
PMID: 38383456
Post-infectious myalgic encephalomyelitis/chronic fatigue syndrome (PI-ME/CFS) is a disabling disorder, yet the clinical phenotype is poorly defined, the pathophysiology is unknown, and no disease-modifying treatments are available. We used rigorous...
3.
Bender M, McPherson A, Phelps C, Pandey S, Laughlin C, Shapira J, et al.
Cell
. 2023 Apr;
186(9):1846-1862.e26.
PMID: 37028428
The use of probiotics by cancer patients is increasing, including among those undergoing immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host crosstalk between probiotic-released aryl hydrocarbon receptor...
4.
Liang H, Jo J, Zhang Z, MacGibeny M, Han J, Proctor D, et al.
Oncotarget
. 2022 Jul;
13:876-889.
PMID: 35875611
Cancer immunotherapy has significantly improved patient survival. Yet, half of patients do not respond to immunotherapy. Gut microbiomes have been linked to clinical responsiveness of melanoma patients on immunotherapies; however,...
5.
McCulloch J, Davar D, Rodrigues R, Badger J, Fang J, Cole A, et al.
Nat Med
. 2022 Mar;
28(3):545-556.
PMID: 35228752
Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but inconsistencies exist between published microbial signatures associated...
6.
Spencer C, McQuade J, Gopalakrishnan V, McCulloch J, Vetizou M, Cogdill A, et al.
Science
. 2021 Dec;
374(6575):1632-1640.
PMID: 34941392
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but the effect of diet and supplements on this interaction is not well studied. We assessed fecal...
7.
McCulloch J, Trinchieri G
Science
. 2021 Oct;
374(6564):154-155.
PMID: 34618567
Testosterone-synthetizing gut bacteria drive resistance to therapy.
8.
Hild B, Dreier M, Oh J, McCulloch J, Badger J, Guo J, et al.
Nat Metab
. 2021 Aug;
3(8):1042-1057.
PMID: 34417593
Obesity and its consequences are among the greatest challenges in healthcare. The gut microbiome is recognized as a key factor in the pathogenesis of obesity. Using a mouse model, we...
9.
Davar D, Dzutsev A, McCulloch J, Rodrigues R, Chauvin J, Morrison R, et al.
Science
. 2021 Feb;
371(6529):595-602.
PMID: 33542131
Anti-programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut microbiota correlates with anti-PD-1 efficacy in preclinical models and...
10.
Stacy A, Andrade-Oliveira V, McCulloch J, Hild B, Oh J, Perez-Chaparro P, et al.
Cell
. 2021 Jan;
184(3):615-627.e17.
PMID: 33453153
The microbiota shields the host against infections in a process known as colonization resistance. How infections themselves shape this fundamental process remains largely unknown. Here, we show that gut microbiota...